Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)
Sponsor: Valley Health System
Summary
This prospective open-label matched-control pilot study evaluates whether inhaled treprostinil improves exercise pulmonary vascular resistance and functional outcomes in adults with interstitial lung disease or connective tissue disease and exercise-induced pulmonary hypertension. Participants will receive inhaled treprostinil plus standard care or standard care alone and will be followed for 6 months, with an optional extension to 12 months.
Official title: Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension: A Prospective Open-Label Matched Control Pilot Trial.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-09
Completion Date
2028-06
Last Updated
2026-09-24
Healthy Volunteers
No
Conditions
Interventions
Treprostinil
Description: * Initial dose 18 mcg four times daily * Titrated to 54-72 mcg four times daily as tolerated Standard disease-specific therapy continues
Standard of Care
Standard management of ILD/CTD without treprostinil.
Locations (2)
The Valley Hospital
Paramus, New Jersey, United States
Valley Medical Group Pulmonary Hypertension Clinic
Paramus, New Jersey, United States